Stockreport

Anteris Technologies Global Highlights DurAVR TAVR Data, PARADIGM Pivotal Trial Plans at TD Cowen Conference [Yahoo! Finance]

Anteris Technologies Global Corp.  (AVR) 
PDF of laminar flow and claimed left-ventricular remodeling (about a 30% LV mass reduction at six months), and a low 3% patient-prosthesis mismatch (PPM) versus ~30% cited f [Read more]